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IDSMC Charter, available upon request.  2 
4 
 
 1 
 2 
What’s already known about this topic? 3 
• Oral systemic immuno-modulatory medication is regularly used off-licence in 4 
children with severe atopic eczema. 5 
• Ciclosporin (CyA) is the commonest first line systemic agent used in this 6 
context, but Methotrexate (MTX) has emerged as an important therapeutic 7 
alternative. 8 
• There is currently no adequately powered randomised controlled trial that 9 
compares both treatments in children. 10 
 11 
What does this study add? 12 
• TREAT addresses this gap and compares the effectiveness, safety, cost-13 
effectiveness and impact on patient’s quality of life of these two drugs. 14 
• TREAT also examines the effects of both drugs using systemic and cutaneous 15 
markers of inflammation and the effect of filaggrin (FLG) genotype and T cell 16 
cytokine signatures on treatment response.  17 
5 
 
Abstract: 1 
 2 
Background:  Oral systemic immuno-modulatory medication is regularly used off-3 
licence in children with severe atopic eczema. However, there is no firm evidence 4 
regarding the effectiveness, safety, cost-effectiveness and impact on quality of life from 5 
an adequately powered randomised controlled trial (RCT) using systemic medication in 6 
children. 7 
Patients/Methods: Multi-centre, parallel group, assessor-blind, pragmatic RCT of 36 8 
week duration with a 24 week follow-up period. 102 children aged 2-16 years with 9 
moderate to severe atopic eczema, unresponsive to topical treatment will be randomised 10 
(1:1) to receive methotrexate (MTX; 0.4mg/kg per week) or ciclosporin (CyA; 11 
4mg/kg/day). The trial has co-primary outcomes: change from baseline to 12 weeks in 12 
Objective Severity Scoring of Atopic Dermatitis (o-SCORAD) and time to first 13 
significant flare following treatment cessation.  14 
Analysis plan: The main aims of the trial are to assess whether there is a difference in 15 
the speed of onset, effectiveness, side-effect profile and reduction in flares post-16 
treatment between CyA and MTX, and, also the cost-effectiveness of the drugs. 17 
Treatment impact on quality of life will also be examined as well as whether FLG 18 
genotype influences treatment response. In addition, the trial studies the immune-19 
metabolic effects of CyA and MTX. 20 
Conclusions: The TREAT trial addresses important therapeutic questions, highlighted 21 
in systematic reviews and treatment guidelines for atopic eczema. The trial design is 22 
pragmatic to reflect current clinical practice. 23 
 24 
  25 
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 1 
Background 2 
Atopic eczema (syn. ‘atopic dermatitis, ‘eczema’) is a chronic, pruritic inflammatory 3 
skin disease, affecting around 20% of UK children, 16% of whom have moderate-severe 4 
disease.1 It comes at a high cost, for patients and families as well as society.2,3 Severe 5 
atopic eczema is often accompanied by significant sleep disturbance, poor school 6 
attendance and social withdrawal, as well as attention-deficit hyperactivity disorder, 7 
anxiety and clinical depression.4 Skin infections are also common in poorly controlled 8 
atopic eczema and a reason for hospital admission.4  9 
Although most cases of atopic eczema are adequately controlled with emollients, topical 10 
anti-inflammatory treatments and/or ultraviolet (UV) therapy, around 2% of children 11 
require oral immuno-suppressive treatment to induce and maintain disease control.5 12 
There are, however, only limited systemic treatment options available and there is 13 
concern about their potential short- and long-term side effects.5 The treatment of severe 14 
atopic eczema in children taskforce survey in 765 consultant dermatologists and 15 
paediatricians from 8 European countries was conducted to establish which systemic 16 
treatment options are available.6 This showed that the first choice systemic immuno-17 
suppressive agent was overall ciclosporin (CyA) with 43%, compared to the UK where 18 
39% use azathioprine (AZA) and 35% use CyA.6 Although MTX was only the third 19 
most commonly used systemic treatment in the survey in the UK, it is increasingly 20 
being used as a first line systemic agent in children, as shown by our most recent 21 
treatment survey in the US.7 Furthermore, while there is significant concern about the 22 
long-term prescribing of CyA (renal toxicity) and AZA (in particular lymphoma and 23 
progressive multifocal leukoencephalopathy), MTX is generally considered well-24 
tolerated and safe in the long-term.5,8 In addition, two RCTs and their follow up studies 25 
suggested no significant difference in efficacy between MTX and AZA in adults and 26 
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MTX and CyA in children, even if CyA appears to show its treatment effect more 1 
quickly.8-11 However, these studies were statistically underpowered.12  2 
There is therefore a clear need to compare MTX with the most established immuno-3 
suppressive medication, CyA, which has also been highlighted in a systematic review.13 4 
Both drugs have demonstrated a reduction in atopic eczema severity and improve 5 
quality of life.4,5,14  6 
The protocol for the trial is presented here and has been written in accordance with the 7 
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 8 
guidelines.15  9 
 10 
Objectives:  11 
The primary objectives are to compare the safety and efficacy of MTX versus CyA, in 12 
recalcitrant atopic eczema in children, during 36 weeks of treatment and to compare 13 
disease control post-treatment cesssation (time to return to baseline disease severity) 14 
over the 24 weeks follow-up period.  Secondary objectives are to examine i) the number 15 
of flares during the trial period as well disease severity throughout follow up, ii) the 16 
impact on quality of life, iii) the effects of both drugs using novel systemic and 17 
cutaneous markers of inflammation during treatment, iv) the effect of filaggrin (FLG) 18 
genotype and T cell cytokine signatures on treatment efficacy, v) the side-effect profiles 19 
of both drugs, and vi) a comparison of the cost effectiveness of both drugs in a health 20 
economic evaluation.  21 
 22 
Patients and methods 23 
Trial design and study setting 24 
TREAT is a phase III multi-centre, parallel group, assessor-blind, pragmatic RCT 25 
aiming to recruit 102 children. Study sites are in 13 secondary and tertiary care 26 
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Paediatric Dermatology Departments across the UK and Ireland (Supplementary Table 1 
S1). 2 
Children are identified in the paediatric dermatology clinics at the study sites. Inclusion 3 
criteria include (see full criteria in Table 1): (i) age 2-16 years; (ii) severe recalcitrant 4 
atopic eczema, defined as an inadequate clinical response to moderate (face) to potent 5 
(body) topical CS and an o-SCORAD severity score ≥30, and (iii) residence within 6 
travelling distance of the recruiting centre.  Exclusion criteria include (see full criteria in 7 
Table 2): (i) serious underlying medical condition; (ii) previous exposure to systemic 8 
immuno-suppressive or biologic agent(s); (iii) recent use of oral CS, phototherapy or 9 
live vaccines.   10 
 11 
Interventions 12 
Participants are randomised to either oral/subcutaneous MTX or oral CyA using an 13 
allocation ratio of 1:1 and will receive the trial drug for a period of 36 weeks and are 14 
followed up for a further 24 weeks following treatment cessation.  15 
 16 
CyA and MTX are commonly used in children for other chronic inflammatory 17 
conditions.  For instance, for severe paediatric psoriasis a dose of 0.4mg/kg/week MTX 18 
(max 25mg per week) is used, as in the TREAT trial (Children’s British National 19 
Formulary).16 The Children’s British National Formulary stipulates a maximum dose for 20 
CyA for severe atopic eczema of 5mg/kg/day, while a dose of 4mg/kg/day is used in the 21 
TREAT trial based on the TREAT survey results.6  22 
 23 
Supplementary Table S2 (supplementary appendix) summarises the formulations of 24 
MTX and CyA used in the study. The assessor who will perform the severity 25 
assessments will be blinded to the trial allocation. 26 
                                                                                                                                                                                                                                                                                                                                                           27 
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Ciclosporin (Neoral brand) 1 
Participants are prescribed 4mg/kg/day given in two divided doses for the treatment 2 
period of 36 weeks. After 12 weeks, dose increases (to a maximum of 5mg/kg/day) or 3 
decreases are allowed, dependent on treatment response. Dose modifications according 4 
to blood pressure and blood test results are detailed in Supplementary Table S3 5 
(supplementary appendix). As Neoral is the only brand with both liquid and capsule 6 
preparations, the brand Neoral was selected for TREAT. 7 
 8 
Methotrexate 9 
Participants are prescribed an initial test dose of 0.1mg/kg at week 0 and then the 10 
therapeutic dose of 0.4mg/kg/week (maximum dose 25mg/week) until week 12, 11 
providing there are no significant side effects and safety blood tests results (see 12 
Supplementary Table S4 (supplementary appendix)).  After week 12, dose 13 
modifications according to treatment response are allowed (maximum dose 14 
25mg/week). Only the 2.5mg strength of MTX tablet will be prescribed and dispensed. 15 
Subcutaneous administration is available to those who suffer significant gastrointestinal 16 
intolerance. Participants on the MTX arm will also be prescribed folic acid 1mg once 17 
daily apart from on the day of MTX administration. Dose modifications according to 18 
blood pressure and blood test results are detailed in Supplementary Table S5 19 
(supplementary appendix). 20 
 21 
Adherence 22 
Participants are instructed to return unused medication, which will be counted and 23 
recorded on the accountability log prior to being disposed/destroyed according to local 24 
NHS policy. If for any reason a participant misses a treatment dose, this will be 25 
documented in the participant diary. 26 
 27 
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Potential side effects 1 
CyA’s main potential side-effect is an increase in blood pressure and nephrotoxicity. 2 
Regular blood pressure and renal function measurements are therefore mandatory in 3 
routine clinical care. To assess renal function more carefully both plasma creatinine and 4 
cystatin C levels are measured in TREAT (at baseline, 2, 8, 12, 36, and 60 weeks) as 5 
well as urinary tubular N-acetyl-beta-D-glucosaminidase (at baseline, 2, 12, 36 and 60 6 
weeks), a sensitive marker of renal tubular function.17 7 
As for MTX, gastrointestinal disturbance (e.g. nausea), liver function abnormalities and 8 
bone-marrow suppression are the main potential side effects. Based on both paediatric 9 
dermatology and rheumatology experience, however, MTX appears to be generally 10 
well-tolerated and safe in children, even in settings where higher doses are used, often 11 
for prolonged time periods and in combination with biologics.4,5,18-21 In TREAT, safety  12 
bloods are taken one week post MTX test dose to capture rare idiosyncratic reactions. In 13 
addition, children in both study arms have safety bloods every two weeks for the first 14 
month, then monthly until week 12 and then eight-weekly thereafter while on treatment, 15 
in keeping with the American Academy of Dermatology guidelines for the use MTX 16 
and CyA in children with severe atopic eczema.22 17 
Drugs known to interact with CyA or MTX may be prescribed when considered 18 
necessary for the patient's safety and well-being. If concomitant drugs are given, careful 19 
monitoring for drug-related adverse effects is recommended, as would be the case in 20 
clinical practice. Since CyA is metabolised by cytochrome p450 (CYP3A) isoenzymes, 21 
in particular CYP3A4, drugs known to significantly alter plasma or whole blood 22 
concentrations of CyA through this route are prohibited during the study. 23 
 24 
Concomitant medication 25 
Participants will continue on their standard eczema care in line with National Institute 26 
for Health and Care Excellence (NICE) guidance, including regular emollients, 27 
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(antiseptic) bath additives and mild-to-potent topical corticosteroids (TCS), topical 1 
calcineurin inhibitors and oral antihistamines of the patient’s/local investigator’s choice. 2 
Rescue oral antibiotics and oral corticosteroids are also permitted. Any medication 3 
required for any ongoing illness and any rescue medications are recorded both during 4 
the treatment and follow up period. Use of wet wraps or other occlusive dressings are 5 
prohibited throughout the study period. 6 
 7 
Outcomes 8 
Primary outcomes:  9 
Two primary outcomes are assessed: 10 
1. The change in atopic eczema severity between baseline & 12 weeks of treatment 11 
in the two treatment arms using the –o-SCORAD, and 12 
2. Time to first flare (defined as time to return to baseline or worse o-SCORAD 13 
score) during the 24 weeks after treatment cessation in the MTX vs CyA groups. 14 
 15 
Secondary outcomes: 16 
1. To examine atopic eczema severity using validated severity scores: Eczema Area and 17 
Severity Index (EASI), Investigators Global Assessment (IGA), o-SCORAD and Patient 18 
Orientated Eczema Measure (POEM) scores between 0 and 12, 36, 48, 60 weeks; 19 
2. To compare the number of flares in each study arm as well as the proportion of 20 
children who re-flared during the 24 weeks after treatment cessation; 21 
3. To study the impact on quality of life through change in Children’s Dermatology Life 22 
Quality Index (CDLQI, children age ≥4 years), Infant’s Dermatology Quality of Life 23 
Index (IDQOL, children <4 years of age), Dermatitis Family Index (DFI) and Child 24 
Health Utility 9D (CHU-9D) scores between 0, 12, 36, 48 and 60 weeks; 25 
4. To determine the proportion of participants achieving 50% improvement in the o-26 
SCORAD and EASI index at 12, 36, 48, and 60 weeks; 27 
13 
 
5. The difference in the proportion of participants withdrawing from treatment due to 1 
adverse events; 2 
6. To assess the cost-effectiveness of CyA vs MTX; 3 
7. To study the immuno-metabolic effects of MTX and CyA, especially in relation to 4 
markers of glycolytic activation and T cell cytokine signature, at baseline, during 5 
treatment and up to 24 weeks after completion of treatment; 6 
8. To compare the drug side effects/toxicity profiles of both MTX and CyA;  7 
9. To examine the association between MTX polyglutamate and CyA trough levels and 8 
reduction in atopic eczema severity as well as drug-related side effects; and 9 
10. To study the impact of FLG genotype (yes/no) on reduction in atopic eczema 10 
severity. 11 
 12 
Sample size 13 
Randomising a total of 102 participants, 51 into each of the study arms, satisfies both of 14 
the following sample size calculations. For the first primary outcome (o-SCORAD), the 15 
change from baseline to 12 weeks will be calculated for each participant. The study 16 
aims to detect a minimum clinically important difference (MCID) of 8 o-SCORAD 17 
points between the two treatment groups, assuming a standard deviation (SD) of 10 18 
(based on the only other paediatric RCT with systemic immuno-suppressive medication 19 
in children which saw a SD of 6.3 (MTX arm) vs 8.9 (CyA arm) at 12 weeks)7 a sample 20 
size of 41 per group, increasing to 49 per group to allow for an estimated 18% loss to 21 
follow up, will be required to provide 90% power using a t-test with a 0.025 two-sided 22 
significance level. The co-primary outcome of this trial is whether or not a patient re-23 
flares following treatment, as this may be an important factor influencing potential 24 
change in prescribing behaviour. The number of patients on CyA burst treatment who 25 
went into remission after three months of treatment in the study by Harper et al was 26 
three out of 21, indicating that 86% of patients re-flared,23 assuming a similar flare risk 27 
14 
 
in our CyA group. A sample size of 43 in each group (51 in each group with estimated 1 
loss to follow up of 18%) will have 80% power to detect a reduction in re-flare of 30% 2 
(from 86% to 56%), using a two-sided test with a 0.025 significance level.  3 
 4 
Recruitment 5 
Participants will be identified by the clinical team at each centre via a search of the 6 
patient database/s or clinic list review. At the routine clinic visit, the patient will be 7 
provided with verbal and written information about the study and instructions on how to 8 
proceed if they are interested in taking part. All patients will be provided with a full 9 
explanation of the trial, before informed written consent/assent is taken.  10 
 11 
Consent 12 
Age-appropriate participant information sheets are provided for parents/guardians and 13 
children (available upon request). The process of obtaining patient assent and 14 
parent/guardian informed consent is in accordance with the Research Ethics Committee 15 
guidance, and Good Clinical Practice (GCP). The investigator, or their nominee 16 
(medically qualified physician), and the participant and/or parent/guardian sign and date 17 
the consent form, before the participant can participate in the study. No trial-specific 18 
procedures are conducted before informed consent has been obtained, and participants 19 
are reminded that they may withdraw from the trial at any time without it affecting the 20 
quality of their care in the future. Information on the collection, storage and use of the 21 
trial samples is provided in the participant information sheets and consent form.  22 
 23 
Confidentiality   24 
Data that contain names or other participant identifiers, such as informed consent forms, 25 
will be stored separately from the case report forms, questionnaires and patient diaries 26 
identified by screening/randomisation numbers. The database will be secured with 27 
15 
 
password-protected access systems. Individual participant medical information obtained 1 
as a result of this study is considered confidential. Participants’ study information will 2 
not be released outside of the study without the written permission of the participant, 3 
except as necessary for monitoring by authorised individuals (i.e. CTRC, Sponsor, 4 
Regulatory Authorities, and NHS Trust) which is clearly stated in the consent form. The 5 
CTRC will preserve the confidentiality of participants taking part in the study and The 6 
University of Liverpool is registered as a Data Controller with the Information 7 
Commissioners Office. 8 
 9 
Screening visit 10 
Informed consent can be taken at or prior to the screening visit, just prior to 11 
assessments. Patients are assigned a screening number for use on study documentation 12 
until randomisation takes place. At screening, a full medical history is taken, with 13 
review of concomitant medication and full assessment against the eligibility criteria as 14 
well as a pregnancy test, where indicated. An o-SCORAD is completed together with 15 
safety bloods. As a safety measure, some patients may require a chest x-ray at the 16 
screening visit if there is a risk of TB exposure, with a radiology report of clear/normal 17 
chest X-ray needed before randomisation occurs. Patients who fail screening, based on 18 
the inclusion/exclusion criteria (see Tables 1 & 2), can be invited for re-screening after 19 
14 days, if appropriate. 20 
 21 
Baseline visit 22 
The baseline visit will occur within a maximum of 14 days of the screening visit. 23 
However, the screening and baseline visit can be carried out on the same day. At this 24 
visit, informed consent status is checked, as is eligibility and a review of concomitant 25 
medication. As per Table 3, the clinician conducts a physical examination and the 26 
blinded assessor completes an o-SCORAD, EASI and IGA. An additional pregnancy 27 
16 
 
test will be performed where indicated. The parent and child complete QoL 1 
questionnaires, POEM, Health related QOL during the visit and are given a patient diary 2 
(including POEM) to complete at home. Blood and urine samples are collected for 3 
safety screening and FLG genotyping and skin tape strips for mechanistic work. (Tape 4 
strips and mechanistic bloods are not collected at all sites.) All participants who provide 5 
consent and fulfil the eligibility criteria (confirmed by a medically qualified physician) 6 
will be randomised by the Local Investigator or their nominee and either CyA or MTX 7 
are dispensed. 8 
 9 
Randomisation method 10 
Participants will be randomised to receive MTX or CyA in a 1:1 ratio at the baseline 11 
visit. Randomisation lists will be generated by an independent statistician using a 12 
computer generated randomisation schedule stratified by site, using a secure (24-hour) 13 
web-based randomisation programme controlled centrally by the CTRC. The block 14 
sizes will not be disclosed in order to ensure allocation concealment.  15 
 16 
Participant timeline 17 
Once the participant is randomised to their allocated treatment during the baseline visit 18 
(week 0), each participant will be enrolled for 60 weeks (36 weeks treatment, followed 19 
by a 24 week observational period).  Details of the timeline for participants are 20 
summarised in Figure 1. 21 
 22 
Blinding 23 
Blinding of the local investigator, research nurse and the participant will not be 24 
possible, as CyA is given in two divided doses daily and MTX only once a week, but 25 
the severity assessors (o-SCORAD, EASI & IGA), are blinded to treatment allocation. 26 
17 
 
At each visit, data are collected as to whether or not the assessment is made blinded. 1 
These data are monitored centrally and reviewed on a regular basis. 2 
 3 
Visit schedule 4 
The schedule for assessments during the treatment and the follow-up phase are shown in 5 
Table 3. 6 
 7 
Participant retention 8 
Participants may withdraw from treatment if the parent/legal representative (or the 9 
participant where applicable) withdraws consent, develops an unacceptable toxicity 10 
based on the Local Investigators judgement, development of illness preventing further 11 
treatment or any change to the participant’s condition that justifies the discontinuation 12 
of treatment. If a participant withdraws from trial treatment then centres will explain the 13 
importance of remaining on trial follow up to allow complete data capture. 14 
 15 
Safety reporting 16 
The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031) 17 
definitions of an adverse event (AE), adverse reaction (AR), serious adverse event, 18 
serious adverse reaction and suspected unexpected serious adverse reaction will be used 19 
during the course of the trial. All adverse events will be reported from randomisation 20 
until four weeks after treatment cessation. Non-serious ARs and AEs should be reported 21 
to the CTRC within seven days of the site being made aware of the event. Serious 22 
ARs/SAEs/SUSARs should be reported to the CTRC within 24 hours of the site being 23 
made aware of the event. SUSARs will be reported to the MHRA by the KHP CTO and 24 
CTRC will notify main REC of all SUSARs. All investigator will be informed of all 25 
SUSARS occurring throughout the course of the study. 26 
 27 
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Mechanistic studies 1 
Immunological parameters will be studied to see if there are significant changes in the 2 
percentages of regulatory T cells, pro/anti-inflammatory cytokine-expressing CD4+ T  3 
cells, or in the corresponding levels of these cytokines in serum following treatment. 4 
Comparison will be made between MTX vs CyA treated patients, and investigation as 5 
to whether there is a correlation between cytokine levels and treatment response at 12 6 
and 36 weeks and the risk of re-flares at 60 weeks. 7 
Systemic metabolic and local skin inflammatory parameters will be studied to see if the 8 
initial treatment response at 12 weeks to MTX (vs CyA) is already associated at that 9 
stage with differences in the systemic metabolic profiles (shift from pro-inflammatory 10 
glycolytic activation to an anti-inflammatory metabolic profile), and whether this is also 11 
seen at 36 and 60 weeks, explaining a more sustained disease remission following MTX 12 
(vs CyA) therapy. Assessment will include whether observed systemic metabolic 13 
changes are associated with corresponding inflammatory profiles in the skin. 14 
Mechanistic blood samples will only be collected from sites that can transport (via 15 
courier) samples to the KCL biobank facility by 4pm on the same day (within maximum 16 
of six hours post venesection). 17 
 18 
Data management 19 
Each centre will undertake training in study requirements before being allowed to open 20 
to recruitment. This will include training on taking informed consent, completion of 21 
CRFs, randomisation and safety reporting. Specific training will also be given on the 22 
severity assessment measures and quality of life questionnaires.  23 
The case report forms (CRF) are the primary data collection instrument and are sent to 24 
CTRC with copies retained at site. A full description of the data management 25 
procedures are provided in the ‘Data Management Plan’ and the ‘Data Entry and 26 
Cleaning Manual’, which can be made available upon request. All identifiable patient 27 
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data is pseudonymised and source data are collected in the patients’ medical records. 1 
Templates of the data collection tools completed by the study site and/or participant, 2 
including CRFs and questionnaires, are available upon request. 3 
 4 
Statistical analysis 5 
A separate statistical analysis plan is available upon request, which details all analyses 6 
to be conducted for both the primary and secondary outcomes and also the methods that 7 
will be used to handle missing data and sensitivity analyses. Below is a brief summary 8 
of these analyses. 9 
The primary analysis will be by intention-to-treat, based on all randomised participants, 10 
as far as is practically possible. The analysis of change in o-SCORAD from baseline to 11 
12 weeks will be examined using analysis of covariance with treatment group and 12 
baseline measurements as covariates.  Analysis of time to first flare post treatment 13 
cessation will be summarised by Kaplan-Meier curves for each treatment group and 14 
compared overall, using the log rank test and survival regression methods. 15 
For the secondary outcomes, continuous data will be reported as the difference in means 16 
and will be analysed using ANCOVA where appropriate and binary data will be 17 
reported in terms of relative risk with appropriate 95% confidence intervals.  Missing 18 
data will be monitored and strategies developed to minimise its occurrence.  The 19 
robustness of the complete case analysis will be assessed using various imputation 20 
assumptions; however these will be informed by data collected on the reasons for 21 
missing data. 22 
This trial will contain an internal pilot study, to check the assumptions made in the 23 
sample size calculation. After the primary outcome data are available from 25 patients 24 
(o-SCORAD index at 12 weeks) the standard deviation of the 25 scores, and the 95% 25 
confidence limits for this estimate, will be calculated without unblinding allocation. If 26 
the 95% confidence limits of the estimate of the standard deviation (SD) of the o-27 
20 
 
SCORAD index at 12 weeks overlap 10 the trial will continue unchanged. If the upper 1 
95% confidence limit of the estimate of the SD of the o-SCORAD index at 12 weeks is 2 
less than 10 the trial will continue unchanged but the Trial Steering Committee (TSC) 3 
will be informed that the trial power is greater than planned. If the lower 95% 4 
confidence limit of the estimate of the SD is greater than 10 the study is underpowered. 5 
The funder will then decide whether to invite an extension or close the study. 6 
 7 
Cost-effectiveness analyses 8 
A within-trial cost-effectiveness analysis will be conducted to assess whether CyA 9 
offers value for money compared to MTX for children with moderate-to-severe AE 10 
using standard methodology24-26 and in accordance with the NICE reference case.27 It 11 
will seek to: 12 
• Estimate resource use and costs in severe paediatric atopic eczema in the MTX 13 
compared to the CyA arm. 14 
• Estimate the Quality-Adjusted Life Years (QALYs) in severe paediatric atopic 15 
eczema in both arms. 16 
• Undertake cost-effectiveness and cost-utility analyses to assess which treatment 17 
represents best value for money for NHS provision. 18 
• Estimate uncertainty levels surrounding the decision on which treatment to 19 
provide. 20 
We will monitor levels of resource use associated with both interventions including 21 
drug costs, monitoring costs and adverse event costs over the 36 weeks treatment 22 
period. In addition, other potentially atopic eczema-related NHS resource items, 23 
including primary care visits, prescriptions, and other health care contacts will be 24 
recorded in participant diaries at baseline and weeks 4, 8, 12, 20, 28, 36, 48 and 60. We 25 
will attach appropriate unit costs to resource use data using published sources for a 26 
common price year28-30 to estimate the mean overall cost per participant per study arm. 27 
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Separately, we will record the time-off work parents take because of their child’s atopic 1 
eczema and cost this using the human capital approach using published average 2 
wages31. Children’s time away from school will be recorded in units of time but not 3 
monetarised. 4 
The economic evaluation will estimate the mean incremental cost and mean incremental 5 
effect of MTX compared to CyA (separate mean incremental effects will be estimated 6 
for: CHU-9D (QALY gain); change in o-SCORAD; and flare number). The base case 7 
analysis will be the cost-utility analysis where QALY for the trial period (based upon 8 
CHU-9D32 instrument) captured at baseline and weeks 12, 36, 48 and 60, using the 9 
proxy version for those aged under 7 years with additional guidance notes for parents of 10 
those aged under 5 years provided by the instrument developer), using linear 11 
interpolation and area under the curve with baseline adjustment.33 12 
Costs and outcomes will be discounted at recommended rates19 in weeks 53 to 60 to 13 
reflect the timeframe greater than 12 months. A regression-based approach (for instance 14 
seemingly-unrelated regression equations if assumptions are met,34 will be used to 15 
estimate the mean incremental cost and effects. Bootstrapping will explore uncertainty 16 
levels associated with the decision to adopt either treatment through the estimation of 17 
cost-effectiveness acceptability curves35. A specific health economics analysis plan will 18 
be written and finalised in advance of the trial database being locked. 19 
 20 
Monitoring 21 
Study data is centrally monitored by the CTRC. A number of monitoring features are in 22 
place at the CTRC to ensure reliability and validity of the trial date, these are detailed in 23 
the ‘Trial Monitoring Plan’, available upon request. On-site monitoring visits can be 24 
triggered if necessary and will be carried out by either representatives of the CTRC or 25 
Sponsor. 26 
 27 
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Ethics and dissemination 1 
Initial review and approval of the trial protocol along with the participant facing 2 
documents were submitted to the East of England – Cambridge East Ethics Committee, 3 
which gave a favourable opinion (16/01/2016). Any subsequent amendments to the 4 
protocol and/or participant facing documents will require ethical approval.  5 
 6 
Protocol Amendments 7 
Protocol amendments are assessed by the Trial Management Group and approved by the 8 
Sponsor, Research Ethics Committees and by the Regulatory Authorities in the UK and 9 
Ireland.  10 
 11 
Summary 12 
TREAT addresses key clinical questions for the management of children with severe 13 
atopic eczema using systemic medication, in particular whether there is a difference in 14 
speed of onset, effectiveness, side-effect profile and reduction in flares post-treatment 15 
between CyA and MTX, and, if so, the cost-effectiveness of the drugs. Furthermore, 16 
TREAT examines mechanistically how both drugs exert their anti-inflammatory profile 17 
systemically and in the skin.  18 
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Dissemination Policy 1 
Trial results 2 
The results from different centres will be analysed together and published as soon as 3 
possible. Individual clinicians must undertake not to submit any part of their individual 4 
data for publication without the prior consent of the TMG. Access to fully anonymised 5 
participant-level datasets and statistical codes can be made by requests to the TMG, 6 
once the final results of the trial have been published. 7 
 8 
Author’s contributions 9 
The TREAT trial was initiated by CF and designed by CF, ADI, PB, FB, APJ, LO’N, 10 
TS, LT, MW, and PRW. CF led on the MRC-NIHR EME grant application, with ADI, 11 
PB, FB, APJ, LO’N, LT, MW, NW, and PRW acting as co-applicants. TS led the NIHR 12 
Research for Patient Benefit application that funds the health economic evaluation in 13 
TREAT, with CF as Co-Principal Investigator. FA, AR-H, CS, and CW reviewed 14 
subsequent versions of the trial protocol, together with the co-applicants. CF is Chief 15 
Investigator of the trial. CF drafted the protocol paper with SB.  16 
All authors reviewed and approved the final version of this paper. For all future papers 17 
the TMG will form the basis of the writing committee and advise on the nature of the 18 
publications. The Uniform Requirements for Manuscripts Submitted to Biomedical 19 
Journals (http://www.icmje.org) will be respected. 20 
 21 
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Appendix 1 
 2 
Trial Steering Committee:  3 
Independent members: Alison Layton (Chair, Consultant Dermatologist & Associate 4 
Medical Director for Research); Tim Burton (Patient & Public Representative); Michael 5 
Grainge (Statistician); Michael Arden-Jones (Dermatologist); Saskia King (Patient & 6 
Public Representative); Michael Perkin (Consultant Paediatric Allergist); Alain Taieb 7 
(Paediatric Dermatologist). Non-independent member: Carsten Flohr (Chief 8 
Investigator), 9 
 10 
Independent Data and Safety Monitoring Committee:  11 
Anthony Ormerod (Chair, Emeritus Professor in Dermatology, University of Aberdeen 12 
and Honorary Consultant Dermatologist NHS Grampian); Robert Chalmers (Honorary 13 
Consultant Dermatologist, Co-Chair and Managing Editor, Dermatology Topic 14 
Advisory Group, WHO ICD Revision Project); Xinxue Liu (Honorary Research 15 
Fellow). 16 
 17 
Trial Management Group: Amina Ahmed (Patient & Public Representative); Farhiya 18 
Ashoor (Trial Manager); Carsten Flohr (Chief Investigator, Chair); Anna Rosala-Hallas 19 
(Trial Statistician); Amy Holton (Sponsor Representative); Alan Irvine (Principal 20 
Investigator); Ashley Jones (Lead Statistician), Tracey Sach (Health Economist); 21 
Catherine Spowart (Supervising Trial Manager); Mandy Wan (Lead Pharmacist); 22 
Charlotte Walker (Lead Research Nurse), Paula Williamson (Director of the Clinical 23 
Trials Research Centre) 24 
 25 
Principal Investigators: Suzannah August (Poole Hospital); Paula Beattie (Royal 26 
Hospital for Children, Glasgow); Sara Brown (Ninewells Hospital, Dundee); Mike Cork 27 
(Sheffield Children’s Hospital); Ben Esdaile (Whittington); Carsten Flohr (Guy’s & St 28 
Thomas’ Hospital); Joanna Gach (University Hospitals Coventry & Warwickshire); 29 
Emma Howard (Birmingham Children’s Hospital); Alan Irvine (Our Lady’s Children’s 30 
Hospital, Dublin);  Tess McPherson (Oxford University Hospitals); Donal O’Kane 31 
(Royal Victoria Hospital, Belfast); Jane Ravenscroft (Nottingham University Hospitals); 32 
Lindsay Shaw (Bristol Royal Hospital for Children). 33 
 34 
Co-Investigators: Caroline Allen (Oxford University Hospitals); Susannah Baron 35 
(Guy’s & St Thomas’ Hospital); Danielle Greenblatt (Guy’s & St Thomas’ Hospital); 36 
Robert Hearn (Ninewells Hospital, Dundee); Susannah Hoey (Royal Victoria Hospital, 37 
Belfast); Rachael Jarret (Oxford University Hospitals); Catherine Jury (Royal Hospital 38 
for Children, Glasgow); Charlie Mitchell (Poole Hospital); Ruth Murphy (Sheffield 39 
Children’s Hospital); Graham Ogg (Oxford University Hospitals); Alice Plant (Poole 40 
Hospital); Louise Newell (Bristol Royal Hospital for Children); Jothsana.Srinivasan 41 
(Nottingham University Hospitals), Emma Wedgeworth (Guy’s & St Thomas’ Hospital) 42 
 43 
Laboratory investigations: 44 
Nicholas Webb (Manchester Royal Infirmary) - provision of expertise on measurement 45 
and assessment of renal function relating to study drug administration; Leonie Taams 46 
(King’s College London) – immunology work; Luke O’Neil (Trinity College Dublin) – 47 
metabolomics; Irwin Mclean (University of Dundee) – FLG mutation analyses.  48 
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Table 1:  TREAT trial inclusion criteria 1 
 2 
1. Written informed consent for study participation obtained from the patient or 
parents/legal guardian, with assent as appropriate by the age/understanding of the 
patient 
 
2. Aged 2-16 years at the time of the screening and randomisation visit 
 
3. Diagnosis of severe, recalcitrant atopic eczema 
 
4. History of inadequate clinical response (in the opinion of the treating clinician) to 
potent topical corticosteroids on the body and moderate strength topical 
corticosteroids on the face. 
5. An objective (o)-SCORAD severity score of at least 30 
 
6. Participants must live within travelling distance of the recruiting centre 
 
7. Females of childbearing potential and males, who are sexually active, must commit 
to consistent and correct use of a highly effective method of contraception (e.g. 
combined hormonal contraception, intrauterine device, physical barrier or abstinence) 
for the duration of the trial and for 6 months after the last dose of study drug. 
 
8. Willingness to comply with study requirements 
 
9. Baseline visit within maximum of 2 weeks of the screening visit 
 
 3 
 4 
5 
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Table 2: TREAT trial exclusion criteria 1 
 2 
1. Serious underlying medical condition 
 
2. Pregnant or nursing (lactating) females 
 
3. Any active and/or chronic infection at screening or baseline (randomisation) 
visit that, based on the investigator's clinical assessment, makes the subject an 
unsuitable candidate for the study 
 
4. Presence of moderate-to-severe impaired renal function as indicated by 
clinically significantly abnormal creatinine (≥ 1.5 x upper normal limit (ULN) 
for age and sex) AND eGFR <60ml/min/1.73m2 at screening visit 
 
5. Clinical evidence of liver disease or liver injury at screening visit as indicated 
by abnormal liver function tests such as AST, ALT, GGT, alkaline phosphatase, 
or serum bilirubin (must not exceed 1.5 x the upper limit value of the normal 
range for age and sex) 
 
6. Total WBC count <3x109/L, or platelets <150x109/L or neutrophils <1.5x109/L 
or haemoglobin <8.5 g/L at screening visit 
 
7. Blood pressure values > 95th percentile for age and sex at screening and baseline 
visit 
 
8. Received systemic corticosteroids within 14 days prior to screening visit and 28 
days of baseline visit 
 
9. Received phototherapy within 4 weeks prior to screening visit and 6 weeks of 
the baseline visit 
 
10. Previous exposure to any biologic agents or systemic immuno-suppressive 
therapy, except for oral corticosteroids for acute flare management 
 
11. Concomitant use of disease-modifying and/or immunosuppressive drugs 
 
12. Received live vaccines within 4 weeks prior to baseline visit 
 
13 Radiology report of abnormal chest x-ray at the screening visit (at the discretion 
of the PI/medically qualified physician) 
14 Receiving treatment with medicines that are substrates for the multidrug efflux 
transporter P-glycoprotein or the organic anion transporter proteins (OATP) for 
which elevated plasma concentrations are associated with serious and/or life-
threatening events; this includes bosentan, dabigatran, etexilate, and aliskiren. 
15 Receiving treatment with products containing Hypericum perforatum (St. John's 
wort) 
16 Receiving oral treatment with tacrolimus, everolimus, sirolimus or lercandipine 
 
17 Currently participating in a conflicting study or participation in a clinical study 
involving a medicinal product in the last 28 days or less than 5 half-lives of the 
medicinal product prior to the screening visit 
18 Known hypersensitivity to methotrexate or ciclosporin products 
19  Insufficient understanding of the trial by the patient and/or parent/guardian 
30 
 
a Collect until 4 weeks 
after treatment stopped. 
b Safety bloods include 
assessment of liver 
function, renal function 
and full blood count.  
c Lipids to also be 
assessed at these time 
points as part of safety 
bloods. 
d Screening chest X-Ray 
on discretion of the 
local PI/medically 
qualified physician in 
those at risk of TB. 
e Collection of blood for 
ciclosporin levels 
should be measured in 
the morning, 12 hours 
(+/-30 minutes) after the 
previous evening’s dose, 
immediately prior to the 
administration of the 
morning dose. In 
younger children, where 
regular ciclosporin 
dosing occurs prior to 
school and in the early 
evening prior to bedtime 
(e.g. 0730 and 1930), on 
the evenings prior to 
study visits where the 
ciclosporin level is to be 
measured, the evening 
dose should be given 
later in accordance with 
the time of the visit 
appointment.  
f Not collected by all 
participating sites  
g Sites that can transport 
samples to King’s 
College London by 4pm 
on the same day and 
within a maximum of 6 
hours post venesection 
only  
h Severity assessments 
only to be collected if an 
unscheduled visit occurs 
between week 36 and 
week 60 
Table 3: Schedule for assessments during the treatment and follow-up phase  1 
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Informed consent x   
 
   
 
    
 
Inclusion/exclusion 
criteria x x  
 
   
 
    
 
Medical history x   
 
   
 
    
 
Concomitant drugs x x x x x x x x x x x x 
x 
Demographics x            
 
Physical exam 
(including mouth/throat 
examination and chest 
auscultation)  x x x x x x x x x x x 
 
o-SCORAD x x   x x x x x x x x 
x h 
EASI, IGA   x   x x x x x x x x 
x h 
POEM (patient 
assessed)  x   x x x x x x x  
 
Parent and child QoL 
(CDLQI/IDQOL & 
DFI)  x     x   x x x 
 
Child HRQL (CHU-9D)  x     x   x x x 
 
Resource Use (patient 
diary)  x   x x x x x x x x 
 
Height & weight  x x x x x x x x x  x 
 
Height x            
 
Blood pressure  x  x x x x x x x  x 
x (only if 
required) 
Adverse events (AE & 
SAE) a   x x x x x x x x   
x 
Safety bloods b xc  x x xc x x x x x  x 
x (only if 
required) 
Chest X-Ray d x            
 
Pregnancy test (beta-
HCG) x x           
 
Confirmation of 
appropriate 
contraception use, 
where applicable  x  x  x  x  x  x  x x x  x  x  x  
x 
Urine sample collection 
(NAG)  x  x   x   x  x 
 
Randomisation  x           
 
Study drug dispensing 
(as needed at each visit)  x   x x x x x    
 
MTX metabolite level 
(blood)    x  x x 
 
 x   
 
CyA trough level 
(blood) e    x  x x 
 
 x   
 
Cystatin C level (blood)  x  x  x x 
 
 x  x 
 
Creatinine level (blood)  x  x  x x 
 
 x  x 
 
Tape stripping for 
cutaneous metabolic 
work f  x     x 
 
 x  x 
 
Collection of blood for 
mechanistic studies g  x     x 
 
 x  x 
 
Collection of  
blood/saliva for FLG 
genotyping  x  
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Figure 1: Patient journey through the TREAT trial 1 
